Go Pro
NASDAQ:VBIO

Valion Bio, Inc. Common Stock Q2 2026 Earnings Report

Valion Bio, Inc. Common Stock logo
$0.30 +0.01 (+3.85%)
As of 07/24/2026 04:00 PM Eastern

Valion Bio, Inc. Common Stock EPS Results

Actual EPS
N/A
Consensus EPS
-$408.00
Beat/Miss
N/A
One Year Ago EPS
N/A

Valion Bio, Inc. Common Stock Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.46 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Valion Bio, Inc. Common Stock Announcement Details

Quarter
Q2 2026
Time
N/A
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Valion Bio, Inc. Common Stock Earnings Headlines

Valion Bio, Inc.
Control 100 shares without spending thousands of dollars
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.tc pixel
See More Valion Bio, Inc. Common Stock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Valion Bio, Inc. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Valion Bio, Inc. Common Stock and other key companies, straight to your email.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use. ClearUP employs a small, ergonomic applicator that is applied externally to designated points on the face for brief treatment sessions. Tivic Health has conducted clinical studies demonstrating significant reductions in sinus pain and congestion, and the device is rechargeable and portable to facilitate daily self-care routines.

Headquartered in northern California, Tivic Health Systems sells ClearUP directly to consumers via its e-commerce platform and through select retail and healthcare distribution partners. The company continues to expand its commercial footprint by forging alliances with pharmacies, online retailers and professional allergy and sinus care networks. While its initial focus has been the U.S. market, Tivic Health is evaluating opportunities for international expansion and additional product indications.

Founded in 2013, Tivic Health completed its initial public offering in October 2020 and is listed on the NASDAQ under the symbol TIVC. The company is led by a management team with deep experience in medical device development, clinical research and healthcare commercialization, all focused on bringing non-invasive therapeutic innovations to patients suffering from chronic sinus and nasal disorders.

View Valion Bio, Inc. Common Stock Profile